Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells

By H. Tazawa, Naoto Tsuchiya, M. Izumiya, H. Nakagama. Proceedings of the National Academy of Sciences of the United States of America, 2007

964 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/7bf0f07d657b783673809d528277888d3d6a6328

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

MicroRNAs in development and disease. (2011, background): “In accordance, overexpression of miR-34 inhibits tumor growth in vivo (603).”
MicroRNA (miRNA) in cancer (2015, background): “…miR-200. miR 15/16, etc. [60,61] and the miR34 family targets cyclin D and E2, CDK4, CDK6, Myc and BCl2 all of which play a major role in promoting cell proliferation, apoptosis and, these observations suggested the possibility that p53-induced miR-34 may negatively regulate cell growth [60,62].”
MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells (2009, positive): “miR-34 mimics resulted in significant G1 and G2/M arrest and a reduction of cells in S phase (Figure 3D), consistent with other reports on miR-34 restoration in various cancer models [6,7,8,10,11,21,22,26].”
miR-34 – a microRNA replacement therapy is headed to the clinic (2012, background): “…et al., 2008), breast (Lodygin et al., 2008; Vogt et al., 2011), pancreas (Chang et al., 2007; Lodygin et al., 2008; Vogt et al., 2011), colon (Tazawa et al., 2007; Lodygin et al., 2008; Vogt et al., 2011), kidney (Lodygin et al., 2008; Vogt et al., 2011), liver (Li et al., 2009; Tryndyak et…”
microRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes (2009, neutral): “Recent work indicates that miR-34a–induced cell cycle arrest could be mediated by the inhibitory effects of miR-34a on E2F3, MYCN, CDK4, cyclin E2, cyclin D1, and BCL2 (30, 31, 34, 38, 39).”
Blinded by the Light: The Growing Complexity of p53. (2009, background): “Satisfyingly, some of the aforementioned studies uncovering p53 regulation of the miRNA locus report markedly lower amounts of miR-34 in some human tumors and tumor-derived cell lines (Bommer et al., 2007; Chang et al., 2007; Tazawa et al., 2007).”
MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death (2008, background): “…deletions in some tumors Increases p53-mediated apoptotic sensitivity CDK4, E2F3 and BCL2a He et al. (2007); Raver-Shapira et al. (2007); Tazawa et al. (2007); Versteeg et al. (1995); Welch et al. (2007); Zanette et al. (2007) miR-34b/c p53 inducible; translational regulation of…”
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review (2012, neutral): “As reported by Tazawa et al (Tazawa et al, 2007), miR-34a transiently inhibits human colon cancer tumour progression when administered subcutaneously in complexes with atelocollagen, which was recently shown to be a very powerful system for efﬁcient in vivo delivery of small interfering RNA molecule”